1. Home
  2. IOVA vs CLVT Comparison

IOVA vs CLVT Comparison

Compare IOVA & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$3.77

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Clarivate Plc

CLVT

Clarivate Plc

HOLD

Current Price

$2.60

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
IOVA
CLVT
Founded
2007
2016
Country
United States
United Kingdom
Employees
N/A
12000
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
IOVA
CLVT
Price
$3.77
$2.60
Analyst Decision
Buy
Hold
Analyst Count
10
7
Target Price
$9.00
$3.22
AVG Volume (30 Days)
13.1M
5.2M
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
14.84
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$51.55
N/A
Revenue Next Year
$37.55
$2.12
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.64
$1.66
52 Week High
$5.63
$4.77

Technical Indicators

Market Signals
Indicator
IOVA
CLVT
Relative Strength Index (RSI) 52.44 59.29
Support Level $2.02 $2.35
Resistance Level $4.34 $2.70
Average True Range (ATR) 0.30 0.15
MACD 0.02 0.01
Stochastic Oscillator 51.69 92.73

Price Performance

Historical Comparison
IOVA
CLVT

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

About CLVT Clarivate Plc

Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.

Share on Social Networks: